Home | Publications | Diseases | CNS place holder
place holder place holder

CNS

Pipeline Insight Migraine

Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries

Publication Date   November 2007
Publisher   Datamonitor
Product Type   Report
Pages   185
ISBN Number   not applicable
Product Code   DAT607
Ask a question about this product?

Price £3,010.00

approximately: $4,470 | €3,542

Summary


Introduction

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharmaceutical sector. It encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector
  • Analyze how Schering-Plough's acquisition of Organon Biosciences will drive notable therapeutic diversification for the company
  • Assess Schering-Plough's continued forecast recovery (CAGR of 7.9% out to 2012) following patent expiry for Claritin in 2001

Content


  • Chapter 1 Executive Summary
    • Key Findings
    • Historical And Forecast Ethical Sales Performance
    • Therapeutic Strategy
    • Launch And Expiry Outlook
    • Externalization, Geographic And Molecule Type Strategies
    • Externalization Strategy
    • Geographic Strategy
    • Molecule Type Strategy
    • Swot Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key Findings
    • Background
    • Key Corporate Developments
    • M&A History
    • Schering Corp Merger With Plough Corp
    • Neogenesis
    • Organon Biosciences
    • M&A Strategy
    • Current Corporate Structure
    • Ethical Pharmaceuticals
    • Consumer Health
    • Animal Health
    • Current Management Team
  • Chapter 3 Historical Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate Analysis, 2001-06
    • Revenue And Growth Rate Vs. Peer Set
    • Product Analysis, 2001-06
    • Growth Drivers
    • Organon M&A
    • Zetia/Vytorin
    • Remicade
    • Growth Resistors
    • Claritin
    • Operating Revenue And Cost Analysis, 2001-06
    • Operating Revenue/Cost Analysis
  • Chapter 4 Forecast Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate, 2006-12
    • Product Analysis, 2006-12
    • Growth Drivers
    • Zetia/Vytorin
    • Mff258
    • Asenapine
    • Nasonex
    • Remicade
    • Sugammadex
    • Growth Resistors
    • Clarinex
    • Rebetol
    • Therapy Area Analysis, 2006-12
    • Cv & Hematology
    • Cns
    • Respiratory
    • Immunology & Inflammation
    • Urology & Sexual Health
    • Therapy Area Focus
    • Launches And Expiries Analysis, 2006-12
    • Launch Portfolio
    • Core Portfolio
    • Expiry Portfolio
    • Launch/Core/Expiry Configuration
    • Externalization Analysis, 2006-12
    • Geographic Analysis, 2006-12
    • Molecule Type Analysis, 2006-12
  • Chapter 5 Key Products And Competitors
    • Key Findings
    • Overview
    • Cardiovascular
    • Zetia/Vytorin
    • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Antidyslipidemic Market Overview
    • Future Market Assessment
    • Respiratory
    • Nasonex/Asmanex (Mometasone Franchise)
    • Overview
    • Sales Forecast
    • News Flow
    • Current Market Assessment
    • Infectious Disease
    • Intron Franchise
    • Overview
    • Sales Forecast
    • News Flow
    • Noxafil
    • Overview
    • Sales Forecast
    • News Flow
    • Urology & Sexual Health
    • Nuvaring
    • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Another Strong Year For Organon's Number One Growth Driver
    • Promotional Drive Remains Key Factor In Nuvaring's Uptake
    • Contraceptive Market Overview
    • Future Market Assessment
    • Puregon
    • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Future Market Assessment
    • Cns
    • Asenapine
    • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Future Market Assessment
    • Sugammadex
    • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Clinical Trial Progression
    • Future Market Assessment
    • Oncology
    • Temodar
    • Overview
    • Sales Forecast
    • News Flow
    • Immunology & Inflammation
    • Remicade
    • Overview
    • Sales Forecast
    • News Flow
    • Golimumab
    • Overview
    • Sales Forecast
    • R&D Pipeline
  • Chapter 6 Appendix
    • Ims Vs. Company-Reported Data Reconciliation
    • References
    • Abbreviations
    • Exchange Rates
  • List Of Tables
    • Table 1: Schering-Plough Corporate Executive Committee
    • Table 2: Peer Set Overview
    • Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
    • Table 4: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Table 5: Product Portfolio Overview, Sales ($M), 2006-12
    • Table 6: Therapy Area Overview, Sales ($M), 2006-12
    • Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
    • Table 8: Core Portfolio Overview, Sales ($M), 2006-12
    • Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
    • Table 10: Externally Developed Portfolio ($M), 2006-12
    • Table 11: Molecule Type Overview, Sales ($M), 2006-12
    • Table 12: Key Products Overview
    • Table 13: Zetia/Vytorin: Overview
    • Table 14: Zetia/Vytorin: Sales Forecast ($M), 2006-12
    • Table 15: Zetia/Vytorin: News Flow
    • Table 16: Antidyslipidemic Market Overview, 7mm Sales ($M), 2006
    • Table 17: Nasonex: Overview
    • Table 18: Asmanex: Overview
    • Table 19: Nasonex: Sales Forecast ($M), 2006-12
    • Table 20: Asmanex: Sales Forecast ($M), 2006-12
    • Table 21: Nasonex/Asmanex: News Flow
    • Table 22: Intron Franchise: Overview
    • Table 23: Rebetol: Overview
    • Table 24: Intron A/Peg-Intron: Sales Forecast ($M), 2006-12
    • Table 25: Rebetol: Sales Forecast ($M), 2006-12
    • Table 26: Intron Franchise: News Flow
    • Table 27: Noxafil: Overview
    • Table 28: Noxafil Sales Forecast ($M), 2006-12
    • Table 29: Noxafil: News Flow
    • Table 30: Nuvaring: Overview
    • Table 31: Nuvaring: Sales Forecast ($M), 2006-12
    • Table 32: Nuvaring: News Flow
    • Table 33: Organon's Non-Dtc Marketing Expenditure In 2006
    • Table 34: Top 10 Contraceptives In 2006 (7mm)
    • Table 35: Puregon/Follistim: Overview
    • Table 36: Puregon/Follistim: Sales Forecast ($M), 2006-12
    • Table 37: Puregon/Follistim: News Flow
    • Table 38: Asenapine: Overview
    • Table 39: Asenapine: Sales Forecast ($M), 2006-12
    • Table 40: Asenapine: News Flow
    • Table 41: Sugammadex: Overview
    • Table 42: Sugammadex: Sales Forecast ($M), 2006-12
    • Table 43: Sugammadex: News Flow
    • Table 44: Temodar/Temodal: Overview
    • Table 45: Temodar: Sales Forecast ($M), 2005-11
    • Table 46: Temodar: News Flow
    • Table 47: Remicade: Overview
    • Table 48: Remicade: Sales Forecast ($M), 2006-12
    • Table 49: Remicade: News Flow
    • Table 50: Golimumab: Overview
    • Table 51: Golimumab: Sales Forecast ($M), 2006-12
    • Table 52: Schering-Plough's R&D Pipeline (Phase I-Registration)
    • Table 53: Schering-Plough's Indication Broadening Pipeline (Phase I-Registration)
    • Table 54: Exchange Rates, 2006
  • List Of Figures
    • Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), Schering-Plough And Big Pharma Peer Set
    • Figure 2: Therapeutic Focus Vs. Big Pharma Peer Set (%), 2006
    • Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Schering-Plough
    • Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Big Pharma
    • Figure 5: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
    • Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
    • Figure 7: Swot Analysis Of Schering-Plough
    • Figure 8: Therapy Area Focus, % Total Sales, 2006
    • Figure 9: Growth Driver By Company, Sales ($M), 2006-12
    • Figure 10: Ethical Sales By Company, Sales ($M), 2006-12
    • Figure 11: Current Corporate Structure
    • Figure 12: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
    • Figure 13: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
    • Figure 14: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
    • Figure 15: Operating Revenue/Cost Analysis ($M), 2001-06
    • Figure 16: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Figure 17: Ethical Revenue ($M) And Growth Rate (%), 2006-12
    • Figure 18: Top Five Products By Sales ($M), 2006
    • Figure 19: Top Five Products By Sales ($M), 2012
    • Figure 20: Growth Drivers And Resistors By Product, 2006-12
    • Figure 21: Key Strategic Products, Sales ($M), 2006-12
    • Figure 22: Ethical Sales By Therapy Area ($M), 2006-12
    • Figure 23: Growth Drivers And Resistors By Therapy Area (%), 2006-12
    • Figure 24: Ethical Sales By Therapy Area ($M), 2006-12
    • Figure 25: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
    • Figure 26: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
    • Figure 27: Launch Schedule, Sales ($M), 2006-12
    • Figure 28: Core Products Sales Growth ($M), 2006-12
    • Figure 29: Expiry Schedule, Sales ($M), 2006-12
    • Figure 30: Launch, Core And Expiry, Sales ($M), 2006-12
    • Figure 31: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Schering-Plough
    • Figure 32: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
    • Figure 33: Externalization Dependency, Sales ($M), 2006-12
    • Figure 34: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
    • Figure 35: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 36: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 37: Geographical Sales Breakdown ($M), 2006-12
    • Figure 38: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
    • Figure 39: Us Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 40: Us Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 41: Molecule Type Sales Breakdown ($M), 2006-12
    • Figure 42: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
    • Figure 43: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 44: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 45: Top Five Antidyslipidemic Drug Quarterly Sales ($M), 7mm, 2006
    • Figure 46: Quarterly Sales($M) Of Top Five Contraceptives, 2006
    • Figure 47: Puregon Vs. Gonal-F, Quarterly Sales ($M), 2003-06
    • Figure 48: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
    • Figure 49: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12